Protective effect of the herbal medicine Gan-fu-kang against carbon tetrachloride-induced liver fibrosis in rats

Molecular Medicine Reports

Volumn 8, Issue 3, 2013, Pages 954-962

  Zhang, Caihua ^a   Wang, Yanfu ^a   Chen, Hong ^a   Yang, Guang ^a   Wang, Shaopeng ^a   Jiang, Miaona ^a   Cong, Li ^a   Yuan, Lijun ^a   Li, Hanshu ^a   Jia, Yujie ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

catenin; Carbon tetrachloride; Gan fu kang; Liver fibrosis; Wnt

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CARBON TETRACHLORIDE; COLLAGEN; GAN FU KANG; GELATINASE A; HERBACEOUS AGENT; LIVER ENZYME; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHINESE MEDICINE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; LIVER FIBROSIS; LIVER PROTECTION; MALE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; TREATMENT DURATION;

ACTINS; ANIMALS; BETA CATENIN; BIOLOGICAL MARKERS; CARBON TETRACHLORIDE; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; DRUGS, CHINESE HERBAL; FEMALE; HERBAL MEDICINE; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASE 2; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84881125061     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1587     Document Type: Article

References (59)

1. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250, 2000.
2. Cheng M and Yang C (eds): The Basic Study and Clinical Research on Hepatic Fibrosis. First edition. First Jumbo Publishing Co., California, USA, 2002.
3. Moreira RK: Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 131: 1728-1734, 2007.
4. Wu J and Zern MA: Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 35: 665-672, 2000.
5. Mann J and Mann DA: Transcriptional regulation of hepatic stellate cells. Adv Drug Deliv Rev 61: 497-512, 2009.
6. Gäbele E, Brenner DA and Rippe RA: Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 8: d69-d77, 2003.
7. Zou YH, Yang Y, Li J, et al: Potential therapeutic effects of a traditional Chinese formulation, BJ-JN, on liver fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol 120: 452-457, 2008.
8. Purps O, Lahme B, Gressner AM, Meindl-Beinker NM and Dooley S: Loss of TGF-beta dependent growth control during HSC transdifferentiation. Biochem Biophys Res Commun 353: 841-847, 2007.
9. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM and Weiskirchen R: Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 46: 1064-1074, 2007.
10. Brewster UC, Setaro JF and Perazella MA: The renin-angiotensin- aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326: 15-24, 2003.
11. Cadigan KM and Nusse R: Wnt signaling: a common theme in animal development. Genes Dev 11: 3286-3305, 1997.
12. Lin X, Zhang S, Huang Q, et al: Protective effect of Fufang-Liu-Yue-Qing, a traditional Chinese herbal formula, on CCl4 induced liver fibrosis in rats. J Ethnopharmacol 142: 548-556, 2012.
13. Xu TT, Jiang MN, Li C, Che Y and Jia YJ: Effect of Chinese traditional compound, Gan-fu-kang, on CCl(4)-induced liver fibrosis in rats and its probable molecular mechanisms. Hepatol Res 37: 221-229, 2007.
14. Gao Y, Song LX, Jiang MN, Ge GY and Jia YJ: Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation 31: 121-132, 2008.
15. Lee PN, Pang K, Matus DQ and Martindale MQ: A WNT of things to come: evolution of Wnt signaling and polarity in cnidarians. Semin Cell Dev Biol 17: 157-167, 2006.
16. Zhao J, Kim KA and Abo A: Tipping the balance: modulating the Wnt pathway for tissue repair. Trends Biotechnol 27: 131-136, 2009.
17. Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129: 199-221, 2003.
18. Kikuchi A and Yamamoto H: Tumor formation due to abnormalities in the β-catenin-independent pathway of Wnt signaling. Cancer Sci 99: 202-208, 2008.
19. Zhang B, Zhou KK and Ma JX: Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway. Diabetes 59: 1809-1816, 2010.
20. Morrisey EE: Wnt signaling and pulmonary fibrosis. Am J Pathol 162: 1393-1397, 2003.
21. Habas R and Dawid IB: Dishevelled and Wnt signaling: is the nucleus the final frontier? J Biol 4: 2, 2005.
22. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004.
23. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL and MacDougald OA: Inhibition of adipogenesis by Wnt signaling. Science 289: 950-953, 2000.
24. Cheng JH, She H, Han YP, et al: Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 294: G39-G49, 2008.
25. Lou JL, Jiang MN, Li C, et al: Herb medicine Gan-fu-kang attenuates liver injury in a rat fibrotic model. J Ethnopharmacol 128: 131-138, 2010.
26. National Institutes of Health: Guide for the Care and Use of Laboratory Animals. Sixth edition. National Acadamies Press, Washington, D.C., 1985.
27. Nie QH, Cheng YQ, Xie YM, Zhou YX and Cao YZ: Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis. World J Gastroenterol 7: 363-369, 2001.
28. Dignani JD, Lebovitz RM and Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983.
29. Castera L: Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol 2: 541-552, 2008.
30. Faria SC, Ganesan K, Mwangi I, et al: MR imaging of liver fibrosis: current state of the art. Radiographics 29: 1615-1635, 2009.
31. Watson MR, Wallace K, Gieling RG, et al: NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J Hepatol 48: 589-597, 2008.
32. Tsukada S, Parsons CJ and Rippe RA: Mechanisms of liver fibrosis. Clin Chim Acta 364: 33-60, 2006.
33. Friedman SL: Liver fibrosis-from bench to bedside. J Hepatol 38: S38-S53, 2003.
34. Fowell AJ and Iredale JP: Emerging therapies for liver fibrosis. Dig Dis 24: 174-183, 2006.
35. Sturgill MG and Lambert GH: Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Clin Chem 43: 1512-1526, 1997.
36. Achliya GS, Wadodkar SG and Dorle AK: Evaluation of hepatoprotective effect of Amalkadi Ghrita against carbon tetrachloride-induced hepatic damage in rats. J Ethnopharmacol 90: 229-232, 2004.
37. Leroy V: Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 32 (6 Suppl 1): 52-57, 2008.
38. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
39. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P and Mallat A: Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45: 605-628, 2005.
40. Li D and Friedman SL: Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 14: 618-633, 1999.
41. Han YP: Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol 21 (Suppl 3): S88-S91, 2006.
42. Lichtinghagen R, Michels D, Haberkorn CI, et al: Matrix metalloproteinase (MMP)-2, MMP-7 and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 34: 239-247, 2001.
43. Arthur MJ, Mann DA and Iredale JP: Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 13: S33-S38, 1998.
44. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
45. Chilosi M, Poletti V, Zamò A, et al: Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 162: 1495-1502, 2003.
46. Königshoff M, Balsara N, Pfaff EM, et al: Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 3: e2142, 2008.
47. Luk JM, Wang X, Liu P, et al: Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 27: 879-890, 2007.
48. He W, Dai C, Li Y, Zeng G, Monga SP and Liu Y: Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20: 765-776, 2009.
49. Brack AS, Conboy MJ, Roy S, et al: Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317: 807-810, 2007.
50. Jiang F, Parsons CJ and Stefanovic B: Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol 45: 401-409, 2006.
51. Myung SJ, Yoon JH, Gwak GY, et al: Wnt signaling enhances the activation and survival of human hepatic stellate cells. FEBS Lett 581: 2954-2958, 2007.
52. Kordes C, Sawitza I and Häussinger D: Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun 367: 116-123, 2008.
53. MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms and diseases. Dev Cell 17: 9-26, 2009.
54. Ying J, Li H, Yu J, et al: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 14: 55-61, 2008.
55. Albrecht JH and Hansen LK: Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes. Cell Growth Differ 10: 397-404, 1999.
56. Houseknecht KL, Cole BM and Steele PJ: Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 22: 1-23, 2002.
57. Galli A, Crabb DW, Ceni E, et al: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940, 2002.
58. Liu J and Farmer SR: Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279: 45020-45027, 2004.
59. Moldes M, Zuo Y, Morrison RF, et al: Peroxisome-proliferator-activated receptor gamma suppresses Wnt/betacatenin signalling during adipogenesis. Biochem J 376: 607-613, 2003.